AU2002361992A1 - 1,4-dihydro-1,4-diphenylpyridine derivatives - Google Patents

1,4-dihydro-1,4-diphenylpyridine derivatives

Info

Publication number
AU2002361992A1
AU2002361992A1 AU2002361992A AU2002361992A AU2002361992A1 AU 2002361992 A1 AU2002361992 A1 AU 2002361992A1 AU 2002361992 A AU2002361992 A AU 2002361992A AU 2002361992 A AU2002361992 A AU 2002361992A AU 2002361992 A1 AU2002361992 A1 AU 2002361992A1
Authority
AU
Australia
Prior art keywords
dihydro
diphenylpyridine
derivatives
diphenylpyridine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002361992A
Other languages
English (en)
Inventor
Swen Allerheiligen
Mary Fitzgerald
Heike Gielen
Volkhart Min-Jian Li
Kevin Nash
Ulrich Rosentreter
Karl-Heinz Schlemmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0130553A external-priority patent/GB2383326A/en
Priority claimed from GB0216664A external-priority patent/GB2390849A/en
Application filed by Bayer AG filed Critical Bayer AG
Publication of AU2002361992A1 publication Critical patent/AU2002361992A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2002361992A 2001-12-20 2002-12-09 1,4-dihydro-1,4-diphenylpyridine derivatives Abandoned AU2002361992A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0130553A GB2383326A (en) 2001-12-20 2001-12-20 Antiinflammatory dihydropyridines
GB0130553.1 2001-12-20
GB0216664A GB2390849A (en) 2002-07-17 2002-07-17 3-Acyl-1,4-dihydro-1,4-di(phenyl/azinyl/diazinyl)pyridine derivatives for use as human neutrophil elastase inhibitors
GB0216664.3 2002-07-17
PCT/EP2002/013931 WO2003053930A1 (en) 2001-12-20 2002-12-09 1,4-dihydro-1,4-diphenylpyridine derivatives

Publications (1)

Publication Number Publication Date
AU2002361992A1 true AU2002361992A1 (en) 2003-07-09

Family

ID=26246892

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002361992A Abandoned AU2002361992A1 (en) 2001-12-20 2002-12-09 1,4-dihydro-1,4-diphenylpyridine derivatives

Country Status (8)

Country Link
US (1) US7199136B2 (https=)
EP (1) EP1458682B1 (https=)
JP (1) JP4486817B2 (https=)
AU (1) AU2002361992A1 (https=)
CA (1) CA2470813A1 (https=)
DE (1) DE60214428T2 (https=)
ES (1) ES2271365T3 (https=)
WO (1) WO2003053930A1 (https=)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0219896D0 (en) 2002-08-27 2002-10-02 Bayer Ag Dihydropyridine derivatives
US7566723B2 (en) * 2002-09-10 2009-07-28 Bayer Healthcare Ag 1-phenyl1-3,4-dihydropyrimidin-2(1H)-one derivatives and their use
SE0302487D0 (sv) * 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
JP5134248B2 (ja) * 2004-02-19 2013-01-30 バイエル・ファルマ・アクチェンゲゼルシャフト ジヒドロピリジノン誘導体
CA2557271C (en) 2004-02-26 2012-08-21 Bayer Healthcare Ag 1,4-diaryl-dihydropyrimidin-2-ones and their use as human neutrophil elastase inhibitors
ES2428503T3 (es) 2004-02-26 2013-11-08 Bayer Intellectual Property Gmbh 1,4-Diaril-dihidropirimidin-2-onas y su uso como inhibidores de elastasa de neutrófilos humanos
BRPI0614290A2 (pt) 2005-08-08 2011-03-22 Argenta Discovery Ltd derivados de biciclo [ 2.2.1 ] hept-7-ilamina e seus usos
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
DE102007019691A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von acyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007019690A1 (de) 2007-04-26 2008-10-30 Bayer Healthcare Ag Verwendung von cyclisch substituierten Furopyrimidin-Derivaten zur Behandlung der pulmonalen arteriellen Hypertonie
DE102007027800A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte bicyclische Heteroaryl-Verbindungen und ihre Verwendung
DE102007027799A1 (de) 2007-06-16 2008-12-18 Bayer Healthcare Ag Substituierte Furopyrimidine und ihre Verwendung
DE102007051762A1 (de) 2007-10-30 2009-05-07 Bayer Healthcare Ag Substituierte Pyrrolotriazine und ihre Verwendung
DE102007054786A1 (de) 2007-11-16 2009-05-20 Bayer Healthcare Ag Trisubstituierte Furopyrimidine und ihre Verwendung
PT2229358E (pt) 2007-12-14 2011-06-29 Pulmagen Therapeutics Asthma Ltd Indoles e sua utilização terapêutica
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
DE102009004197A1 (de) * 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
SG174134A1 (en) 2009-02-17 2011-10-28 Chiesi Farma Spa Triazolopyridine derivatives as p38 map kinase inhibitors
GB0918924D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Azaindole derivatives
GB0918922D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminopyridine derivatives
GB0918923D0 (en) 2009-10-28 2009-12-16 Vantia Ltd Aminothiazole derivatives
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
DK2788349T3 (en) 2011-12-09 2017-01-30 Chiesi Farm Spa kinase inhibitors
KR20140105459A (ko) 2011-12-09 2014-09-01 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
BR112014013178A2 (pt) 2011-12-09 2017-06-13 Chiesi Farm Spa composto, composição farmacêutica e uso de um composto
US20140221335A1 (en) 2013-02-06 2014-08-07 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9115093B2 (en) 2013-03-04 2015-08-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
RU2015151886A (ru) 2013-06-06 2017-06-08 КЬЕЗИ ФАРМАЧЕУТИЧИ С.п.А. Ингибиторы киназ
US9440930B2 (en) 2014-07-31 2016-09-13 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9475779B2 (en) 2014-07-31 2016-10-25 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9290457B2 (en) * 2014-07-31 2016-03-22 Boehringer Ingelheim International Gmbh Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9657015B2 (en) 2014-07-31 2017-05-23 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9458113B2 (en) 2014-07-31 2016-10-04 Boehringer Ingelheim International Gmbh Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activity
US9958484B2 (en) * 2015-07-08 2018-05-01 Qualcomm Incorporated Apparatus and method for measuring load current by applying compensated gain to voltage derived from drain-to-source voltage of power gating device
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
EP3394059B1 (en) 2015-12-23 2020-11-25 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-phenyl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro- naphthalen-1-yl)-urea derivatives and their use as p38 mapk inhibitors
AR107164A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa INHIBIDORES DE QUINASA p38
EP3394058B1 (en) 2015-12-23 2020-10-14 Chiesi Farmaceutici S.p.A. N-[3-(3-{4-[[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl} -ureido)-phenyl]-methanesulfonamide derivatives and their use as p38 mapk inhibitors
JP7034942B2 (ja) 2016-05-05 2022-03-14 エフ．ホフマン－ラ ロシュ アーゲー ピラゾール誘導体、その組成物及び治療的使用
CN109890817B (zh) 2016-09-06 2022-06-17 豪夫迈·罗氏有限公司 8-(氮杂环丁烷-1-基)-[1,2,4]三唑并[1,5-a]吡啶基化合物、其组合物和应用方法
EP3562809B1 (en) 2016-12-29 2021-06-09 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds and methods of use thereof
CN110494434B (zh) 2017-03-14 2022-05-24 豪夫迈·罗氏有限公司 吡唑并氯苯基化合物、其组合物及其使用方法
CN110678467B (zh) 2017-05-22 2023-06-13 豪夫迈·罗氏有限公司 治疗化合物和组合物及其使用方法
WO2018215389A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
EP3740488A1 (en) 2018-01-15 2020-11-25 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds as jak inhibitors
JP2020015705A (ja) * 2018-07-27 2020-01-30 住友化学株式会社 アニリン化合物の製造方法
US20200399274A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Tetrazole-substituted pyrazolopyrimidine inhibitors of jak kinases and uses thereof
WO2020257143A1 (en) 2019-06-18 2020-12-24 Genentech, Inc. Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
CA3140024A1 (en) 2019-06-18 2020-12-24 Mark Edward Zak Pyrazolopyrimidine sulfone inhibitors of jak kinases and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2753946A1 (de) * 1977-12-03 1979-06-13 Bayer Ag 1-n-aryl-1,4-dihydropyridine und ihre verwendung als arzneimittel
DE3222367A1 (de) * 1982-06-15 1983-12-15 Bayer Ag, 5090 Leverkusen Verwendung von 1,4-dihydropyridinen in antiarteriosklerotika und deren herstellung
DE4011695A1 (de) * 1990-04-11 1991-10-17 Bayer Ag Verwendung von n-alkylierten 1,4-dihydropyridindicarbonsaeureestern als arzneimittel, neue verbindungen und verfahren zu ihrer herstellung
DE4328884A1 (de) * 1993-08-27 1995-03-02 Bayer Ag Verwendung von N-alkylierten 1,4-Dihydropyridincarbonsäureestern als Arzneimittel
JP3337829B2 (ja) * 1994-07-29 2002-10-28 日研化学株式会社 １，４−ジヒドロピリジン化合物

Also Published As

Publication number Publication date
CA2470813A1 (en) 2003-07-03
US7199136B2 (en) 2007-04-03
JP4486817B2 (ja) 2010-06-23
US20050165014A1 (en) 2005-07-28
DE60214428T2 (de) 2007-09-20
DE60214428D1 (de) 2006-10-12
WO2003053930A1 (en) 2003-07-03
EP1458682B1 (en) 2006-08-30
EP1458682A1 (en) 2004-09-22
JP2005517666A (ja) 2005-06-16
ES2271365T3 (es) 2007-04-16

Similar Documents

Publication Publication Date Title
AU2002361992A1 (en) 1,4-dihydro-1,4-diphenylpyridine derivatives
AU2001230026A1 (en) 2,4-diaminothiazole derivatives
AU2002349676A1 (en) 4-oxoquinoline derivatives
AU2002359923A1 (en) 6-fluorobicyclo[3.1.0]hexane derivatives
AU2001280099A1 (en) 4-acylaminopyrazole derivatives
AU2001230584A1 (en) 1h-imidazopyridine derivatives
AU2001230537A1 (en) Pyridoxazine derivatives
AU2001281802A1 (en) 6-phenylpyrrolopyrimidinedione derivatives
AU2001278790A1 (en) 1h-imidazopyridine derivatives
AU2002367323A1 (en) Benzothieno (3,2-
AU2003247706A1 (en) 6, 11-4-carbon bridged erythromycin derivatives
AU2001254661A1 (en) Aminosulfonylbiphenyl derivatives
AU2001230565A1 (en) Perfluoroisopropylbenzene derivatives
AU2003269949A1 (en) Substituted 1,4-pyrazine derivatives
AU2003258598A1 (en) Substituted 1,2,3,4-tetrahydroquinoline derivatives
AU2002363600A1 (en) Novel phenyl-propargylether derivatives
AU2001242772A1 (en) 3-substituted-4-pyrimidone derivatives
AU2002218400A1 (en) 3-substituted 2,7-naphthyridin-1-yl derivatives
AU2002358715A1 (en) Tetrahydrobenzfluorene derivatives
AU2001289782A1 (en) Pyrrolotriazolopyrimidinone derivatives
AU2001256791A1 (en) 5,6-trans-2-alkylvitamin d derivatives
AU2001241084A1 (en) Imidazolylbenzophenone derivatives
AU2002327093A1 (en) 1,2-dihydro-2-oxo-1,8-naphthyridine derivative
AU2002361027A1 (en) Substituted 1,5-diaminopentan-3-ol compounds
IL159965A0 (en) Novel 2,4-diaminothiazole derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase